Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07215702 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

A Phase 2 study of Sepsis and Acute Kidney Injury, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
124
Enrollment target
20
Study locations

NCT07215702 is a Phase 2 study of Sepsis and Acute Kidney Injury that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 124 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07215702, a Phase 2 study of Sepsis and Acute Kidney Injury, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
124 participants
Enrollment target
20
Study locations

Study Summary

This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.

Conditions Studied

Sepsis Acute Kidney Injury

Interventions

  • DRUG Placebo
  • DRUG AZD4144

Study Locations (20)

Other

  • Research Site - CABA
  • Research Site - Ciudad de Buenos Aires
  • Research Site - La Plata
  • Research Site - Rosario

New York

  • Research Site - The Bronx
  • Research Site - The Bronx
  • Research Site - The Bronx

North Carolina

  • Research Site - Chapel Hill
  • Research Site - Winston-Salem

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Pittsburgh

Arizona

  • Research Site - Tucson

California

  • Research Site - Newport Beach

Kansas

  • Research Site - Kansas City

Maryland

  • Research Site - Baltimore

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2026-02-10
Est. Completion 2027-02-11
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07215702

The ClinicalTrials.gov registry entry for NCT07215702 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07215702 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT07215702 about?

NCT07215702 is a clinical study titled "A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.". This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly...

What is the current status of trial NCT07215702?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2026-02-10. Estimated completion is 2027-02-11.

What conditions does trial NCT07215702 study?

This clinical trial studies the following conditions: Sepsis, Acute Kidney Injury.

What interventions are being tested in trial NCT07215702?

The interventions under investigation include: Placebo (DRUG), AZD4144 (DRUG).

Who is sponsoring clinical trial NCT07215702?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07215702 being conducted?

This trial has 20 study locations across Arizona, California, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sepsis

All registered trials for this condition

Acute Kidney Injury

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.